vs
Side-by-side financial comparison of MARKETWISE, INC. (MKTW) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
MARKETWISE, INC. is the larger business by last-quarter revenue ($83.4M vs $60.1M, roughly 1.4× RHYTHM PHARMACEUTICALS, INC.). MARKETWISE, INC. runs the higher net margin — 2.3% vs -92.6%, a 94.9% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (83.8% vs -14.4%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (43.8% CAGR vs -12.5%).
MarketWise Inc. is a leading provider of investment research, financial market data, and wealth management education solutions. It serves both retail and institutional investors across North America, Europe, and the Asia-Pacific region, offering actionable market insights, portfolio analysis tools, and specialized multi-asset research.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
MKTW vs RYTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $83.4M | $60.1M |
| Net Profit | $1.9M | $-55.6M |
| Gross Margin | 87.0% | 88.1% |
| Operating Margin | 15.8% | -87.1% |
| Net Margin | 2.3% | -92.6% |
| Revenue YoY | -14.4% | 83.8% |
| Net Profit YoY | -9.8% | — |
| EPS (diluted) | $0.79 | $-0.83 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $60.1M | ||
| Q4 25 | $83.4M | $57.3M | ||
| Q3 25 | $81.3M | $51.3M | ||
| Q2 25 | $80.0M | $48.5M | ||
| Q1 25 | $83.5M | $32.7M | ||
| Q4 24 | $97.5M | $41.8M | ||
| Q3 24 | $97.2M | $33.3M | ||
| Q2 24 | $105.0M | $29.1M |
| Q1 26 | — | $-55.6M | ||
| Q4 25 | $1.9M | $-47.5M | ||
| Q3 25 | $1.5M | $-52.9M | ||
| Q2 25 | $1.3M | $-46.6M | ||
| Q1 25 | $890.0K | $-49.5M | ||
| Q4 24 | $2.1M | $-43.3M | ||
| Q3 24 | $1.7M | $-43.6M | ||
| Q2 24 | $1.5M | $-32.3M |
| Q1 26 | — | 88.1% | ||
| Q4 25 | 87.0% | 91.6% | ||
| Q3 25 | 87.0% | 89.3% | ||
| Q2 25 | 86.3% | 88.6% | ||
| Q1 25 | 85.7% | 88.8% | ||
| Q4 24 | 88.7% | 90.9% | ||
| Q3 24 | 86.7% | 88.5% | ||
| Q2 24 | 87.3% | 89.9% |
| Q1 26 | — | -87.1% | ||
| Q4 25 | 15.8% | -82.2% | ||
| Q3 25 | 21.9% | -102.6% | ||
| Q2 25 | 18.5% | -93.4% | ||
| Q1 25 | 20.1% | -143.7% | ||
| Q4 24 | 24.8% | -98.6% | ||
| Q3 24 | 22.5% | -132.0% | ||
| Q2 24 | 20.3% | -139.2% |
| Q1 26 | — | -92.6% | ||
| Q4 25 | 2.3% | -83.0% | ||
| Q3 25 | 1.9% | -103.1% | ||
| Q2 25 | 1.6% | -96.1% | ||
| Q1 25 | 1.1% | -151.4% | ||
| Q4 24 | 2.2% | -103.6% | ||
| Q3 24 | 1.8% | -131.2% | ||
| Q2 24 | 1.5% | -110.9% |
| Q1 26 | — | $-0.83 | ||
| Q4 25 | $0.79 | $-0.73 | ||
| Q3 25 | $0.58 | $-0.82 | ||
| Q2 25 | $0.53 | $-0.75 | ||
| Q1 25 | $0.41 | $-0.81 | ||
| Q4 24 | $1.06 | $-0.71 | ||
| Q3 24 | $0.87 | $-0.73 | ||
| Q2 24 | $0.80 | $-0.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $70.1M | $340.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-11.7M | $122.9M |
| Total Assets | $218.4M | $442.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $340.6M | ||
| Q4 25 | $70.1M | $388.9M | ||
| Q3 25 | $50.5M | $416.1M | ||
| Q2 25 | $69.1M | $291.0M | ||
| Q1 25 | $79.2M | $314.5M | ||
| Q4 24 | $97.9M | $320.6M | ||
| Q3 24 | $94.1M | $298.4M | ||
| Q2 24 | $109.3M | $319.1M |
| Q1 26 | — | $122.9M | ||
| Q4 25 | $-11.7M | $139.1M | ||
| Q3 25 | $-14.5M | $148.8M | ||
| Q2 25 | $-15.8M | $-11.9M | ||
| Q1 25 | $-15.8M | $18.9M | ||
| Q4 24 | $-12.5M | $21.7M | ||
| Q3 24 | $-19.5M | $11.2M | ||
| Q2 24 | $-23.7M | $39.3M |
| Q1 26 | — | $442.3M | ||
| Q4 25 | $218.4M | $480.2M | ||
| Q3 25 | $201.7M | $506.9M | ||
| Q2 25 | $211.8M | $372.7M | ||
| Q1 25 | $239.6M | $386.7M | ||
| Q4 24 | $259.5M | $392.3M | ||
| Q3 24 | $278.4M | $363.6M | ||
| Q2 24 | $315.3M | $381.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $46.0M | — |
| Free Cash FlowOCF − Capex | $45.6M | — |
| FCF MarginFCF / Revenue | 54.6% | — |
| Capex IntensityCapex / Revenue | 0.5% | — |
| Cash ConversionOCF / Net Profit | 23.84× | — |
| TTM Free Cash FlowTrailing 4 quarters | $67.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $46.0M | $-25.4M | ||
| Q3 25 | $2.2M | $-26.6M | ||
| Q2 25 | $17.8M | $-23.3M | ||
| Q1 25 | $1.7M | $-40.4M | ||
| Q4 24 | $-22.1M | $-18.8M | ||
| Q3 24 | $-5.8M | $-25.2M | ||
| Q2 24 | $-3.8M | $-29.1M |
| Q1 26 | — | — | ||
| Q4 25 | $45.6M | — | ||
| Q3 25 | $2.2M | — | ||
| Q2 25 | $17.7M | — | ||
| Q1 25 | $1.7M | — | ||
| Q4 24 | $-22.3M | — | ||
| Q3 24 | $-5.9M | — | ||
| Q2 24 | $-3.8M | — |
| Q1 26 | — | — | ||
| Q4 25 | 54.6% | — | ||
| Q3 25 | 2.7% | — | ||
| Q2 25 | 22.2% | — | ||
| Q1 25 | 2.0% | — | ||
| Q4 24 | -22.9% | — | ||
| Q3 24 | -6.0% | — | ||
| Q2 24 | -3.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — |
| Q1 26 | — | — | ||
| Q4 25 | 23.84× | — | ||
| Q3 25 | 1.44× | — | ||
| Q2 25 | 13.76× | — | ||
| Q1 25 | 1.95× | — | ||
| Q4 24 | -10.36× | — | ||
| Q3 24 | -3.39× | — | ||
| Q2 24 | -2.46× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
